Brief: Gri Bio Inc - IDMC Recommends Continuation Of Study With No Safety Concerns
01/04/2025 14:01
April 1 (Reuters) - GRI Bio Inc GRI.O: GRI BIO REPORTS ENCOURAGING INTERIM 2-WEEK SAFETY RESULTS FROM ONGOING PHASE 2A STUDY OF GRI-0621 IN IDIOPATHIC PULMONARY FIBROSIS (“IPF”) GRI BIO INC - IDMC RECOMMENDS CONTINUATION OF STUDY WITH NO SAFETY CONCERNS GRI BIO INC - GRI-0621 SAFE AND WELL-TOLERATED IN FIRST 12 PATIENTS GRI BIO INC - INTERIM BIOMARKER DATA EXPECTED Q2 2025, TOPLINE RESULTS Q3 2025 Source text: ID:nGNXbWg3v4 Further company coverage: GRI.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on GRI Bio
See all newsGRI Bio Inc reports results for the quarter ended June 30 - Earnings Summary
GRI Bio Inc expected to post a loss of $1.19 a share - Earnings Preview
Brief: Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis
GRI Bio Q1 net loss narrows on lower R&D expenses
GRI Bio raises $14.5 mln to fund operations into Q1 2027